CG Oncology
PublicCG Oncology is now publicly traded
The data on this page reflects CG Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 24, 2024
Last Round
Follow-on Offering
Dec 16, 2024
Total Funding Raised
$1.2B
Company Overview
CG Oncology (NAS: CGON) is a biopharmaceutical company dedicated to developing and commercializing innovative bladder-sparing therapies for patients with bladder cancer.
Sector
Biotech
AI Layer
Non-AI
Keywords
CG Oncology Comparables
Compare CG Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abalos Therapeutics | 52% | |
| Emtora Biosciences | 51% | |
| Omios Biologics | 51% |
CG Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 16, 2024 | ||||
| IPO | Jan 24, 2024 | ||||
| Crossover Round | Aug 2, 2023 | ||||
| Crossover Financing | Aug 2, 2023 | ||||
| Series F | Jul 1, 2023 | ||||
Series E | Nov 15, 2022 |
CG Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series E |
| Longitude Capital | Series F, Crossover Financing, Crossover Round, Series E |
| Janus Henderson Group | Series F, Crossover Financing, Crossover Round |
| RA Capital Management | Series F, Crossover Financing, Crossover Round, Series E |
| TCG Crossover | Series F, Crossover Financing, Crossover Round |
| Morgan Stanley & Co., LLC | Follow-on Offering |
| Camford Capital | Series D |
CG Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access